BSE Sensex 30 Stocks Regulatory Filings — September 28, 2026

Acquired remaining 52.5% of Sproutlife Foods for ~₹645 cr (cash), making it a wholly owned subsidiary. Sproutlife's revenue surged from ₹108 cr (FY24) to ₹452 cr (FY26), a 318% growth in 2 years, but the deal values it at ~43x FY26 sales, a steep premium reflecting ITC's urgency to dominate the health-foods space

Signed exclusive licensing deal for lerodalcibep (Lyrokaul), a once-monthly PCSK9 inhibitor, for ex-US/China markets. EU approval received Sep 21, 2026. Addressable market is $3.7B growing at 38% CAGR. This could add $500M+ in peak sales, significantly boosting the Innovative Medicines portfolio

ICRA reaffirmed [ICRA]AAA (Stable) rating; company remains net debt-free (ex-MMFSL). EV market share improved to 28.3%, and all 3 EV models qualified for PLI benefits in Q1 FY27. EV business is EBIT-positive before PLI, indicating strong operational leverage

Acquired Robotiq.ai for EUR 9M (cash) to add enterprise RPA to HCL UnO Agentic. Target revenue is only EUR 1.4M (FY25), but the deal is tiny (0.02% of HCL's market cap) and strategically fills a capability gap in AI orchestration

Sproutlife acquisition is not a related-party transaction and required no regulatory approvals, enabling swift integration. ITC is aggressively pivoting its foods portfolio toward premium, health-oriented brands, a high-growth segment

Lerodalcibep is already US FDA-approved (brand Lerochol), de-risking the regulatory pathway. Sun Pharma gets manufacturing rights, providing margin control. The deal excludes China, avoiding the most competitive biosimilar market

Plans significant capex of ₹20,000-25,000 cr for FY2027-28, signaling confidence in demand. ICRA noted intense competition but M&M's strong credit profile supports this investment cycle

The AI research study (1,066 AI personas) found 84% of wealth firms need an operating model reset but <10% are prepared. HCL is positioning itself as the go-to partner for this transformation, creating a large TAM

Both closed trading windows from Oct 1, 2026, until 2 days after Q2 FY27 results. This is routine but signals results are due in late October, a key catalyst for the financial sector

CCI hearing adjourned to Nov 2, 2026. While no financial impact disclosed, the prolonged regulatory overhang (since Jul 30, 2026) creates uncertainty and could weigh on sentiment

The ₹645 cr acquisition values Sproutlife at ~43x FY26 revenue of ₹452 cr. Even with 318% growth over 2 years, this is a rich multiple. If growth decelerates, ITC may face goodwill impairment risk

The CCI matter has been ongoing since at least Jul 30, 2026, with no resolution. The adjournment to Nov 2, 2026, extends uncertainty. Potential penalties or business practice changes could impact profitability

The ₹20,000-25,000 cr capex plan for FY2027-28 is substantial. If auto demand weakens or EV adoption slows, M&M could face margin pressure and elevated leverage, despite current net-debt-free status

The PCSK9 inhibitor market is competitive (Amgen's Repatha, Sanofi's Praluent). Lerodalcibep's once-monthly dosing is an advantage, but biosimilars are emerging. Sun Pharma's confidential financial terms could hide unfavorable economics

The Robotiq.ai acquisition (EUR 9M) is immaterial to HCL's financials (revenue ~$13B). It may not move the needle and could be a distraction if integration fails or the technology doesn't scale

The KMP contact update is routine, but any failure in timely disclosure of material events by these KMPs could lead to SEBI penalties. No immediate risk, but governance is key for financials

Trading window closures are standard, but any leak of Q2 results before the official announcement could trigger insider trading investigations. The window closure period (Oct 1 to ~late Oct) is a blackout period

The resolution was approved by requisite majority, but the filing did not disclose the nature of the resolution. If it was a contentious issue (e.g., related-party transaction, remuneration), the lack of detail could mask governance concerns

The AI study is a marketing initiative, not a financial filing. Over-reliance on its findings (84% need reset, <10% prepared) could lead to over-optimistic revenue projections for HCL's consulting business

Sproutlife's 'Yoga Bar' brand gives ITC a direct entry into the ₹5,000 cr+ health snack market growing at 20%+ CAGR. ITC's distribution muscle can scale Sproutlife's ₹452 cr revenue to ₹1,500 cr+ in 3 years, making the 43x multiple look cheap

Lerodalcibep targets a $3.7B ex-US/China market growing at 38% CAGR. Sun Pharma's strong emerging market presence can capture significant share. If peak sales reach $500M, at a conservative 5x sales multiple, this deal could add ₹2,500 cr to Sun's valuation

With 28.3% e-SUV market share and PLI benefits, M&M is well-positioned in India's EV transition. The net-debt-free status and AAA rating allow cheap debt financing for the ₹20,000-25,000 cr capex, potentially yielding high ROE as EV margins improve

The Robotiq.ai acquisition, though small, fills a critical gap in HCL's AI orchestration platform. As enterprises move from AI experimentation to execution, HCL's integrated decision-to-execution capability could win large deals, driving 12-15% growth in its software division

Post-acquisition, Sproutlife becomes a wholly owned subsidiary, allowing ITC to fully consolidate its fast-growing revenue and potentially improve overall FMCG margins. ITC's FMCG segment could see a 50-100 bps margin uplift as Sproutlife scales

The deal includes manufacturing rights, giving Sun Pharma cost control and supply chain security. This is a key differentiator vs. pure licensing deals, potentially yielding 60%+ gross margins on the product

Trading window closures signal Q2 FY27 results in late October. Bajaj Finance has consistently delivered 25%+ YoY AUM growth. Any positive surprise (e.g., NIM stability, lower credit costs) could trigger a rally in both stocks

M&M holds 58.97% in SML Mahindra (as of Jun 30, 2026). Any value unlocking (e.g., IPO, stake sale) could provide a special dividend or buyback catalyst, given M&M's strong cash position

ITC's full acquisition of Sproutlife at a premium multiple (43x sales) reflects a broader trend of large FMCG players acquiring high-growth health/wellness brands to capture premiumization. This could trigger similar moves by HUL, Nestlé, and Britannia, driving up valuations in the health-foods space.

Sun Pharma's PCSK9 deal exemplifies Indian pharma's shift from generics to innovative drugs via licensing. With a $3.7B TAM growing at 38% CAGR, this strategy can deliver 15-20% revenue growth for innovators, but carries execution risk. Watch for similar deals from Dr. Reddy's and Cipla.

M&M (AAA-rated, net-debt-free, EV leader) contrasts sharply with Maruti Suzuki (regulatory overhang, CCI hearing). The auto sector is bifurcating between strong balance sheet players investing in EV/capex and those facing structural/regulatory headwinds. Investors should favor the former.

HCL's EUR 9M Robotiq.ai acquisition is a pattern—small, targeted buys to fill AI/automation gaps (vs. large, risky M&A). Infosys, TCS, and Wipro are likely to follow similar 'string of pearls' strategies, keeping deal sizes small but cumulative impact meaningful.

7 of 12 filings were low-materiality (trading window closures, KMP updates, postal ballot results). This is typical ahead of Q2 results (late Oct). The lack of major operational updates suggests companies are in a quiet period, making the few strategic announcements (ITC, Sun Pharma, HCL) even more significant.

Adjourned to Nov 2, 2026. Any adverse ruling could impact pricing, dealer agreements, or competitive practices. Watch for pre-hearing settlements or management commentary.

EU approval received Sep 21, 2026. Monitor launch timelines in key EU markets and any early revenue guidance. First-quarter sales post-launch will be critical.

Watch for Q3 FY27 updates on Sproutlife's revenue run-rate and margin trajectory. Any guidance on scaling from ₹452 cr to ₹1,000 cr+ would be a positive catalyst.

The ₹20,000-25,000 cr capex plan for FY2027-28 is ambitious. Monitor quarterly capex spend and EV sales data. Any delays or cost overruns could pressure the stock.

Trading window closes Oct 1, 2026. Results expected late October. Key metrics: AUM growth, NIMs, credit costs. Any positive surprise could drive 5-8% upside.

Deal close expected by end of November 2026. Watch for client wins or product launches leveraging the combined AI+RPA platform. Small deal, but strategic importance is high.

Updated KMP contacts for material event disclosure. Monitor for any material events (e.g., M&A, leadership changes) that these KMPs would need to disclose. No immediate catalyst, but governance watch.

The nature of the approved resolution was not disclosed. If it was a significant related-party transaction or remuneration increase, details may emerge in the next filing. Watch for any shareholder dissent.